ABO-incompatible kidney transplantation

Fehr, Thomas; Stüssi, Georg

doi:10.1097/mot.0b013e328355f013

Cited by 11 publications

(12 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…). In the case of rituximab, the pages not only explain its role in treating CD20‐positive non‐Hodgkin's lymphoma and chronic lymphocytic leukaemia, but highlight its role in several other autoimmune conditions and in the suppression of antibody‐mediated organ rejection …”

Section: The Iuphar Guide To Immunopharmacology: Accessing the Datamentioning

confidence: 99%

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

et al. 2020

View full text Add to dashboard Cite

Given the critical role that the immune system plays in a multitude of diseases, having a clear understanding of the pharmacology of the immune system is crucial to new drug discovery and development. Here we describe the International Union of Basic and Clinical Pharmacology (IUPHAR) Guide to Immunopharmacology (GtoImmuPdb), which connects expert-curated pharmacology with key immunological concepts and aims to put pharmacological data into the hands of immunologists. In the pursuit of new therapeutics, pharmacological databases are a vital resource to researchers through providing accurate information on the fundamental science underlying drug action. This extension to the existing IUPHAR/British Pharmacological Society Guide to Pharmacology supports research into the development of drugs targeted at modulating immune, inflammatory or infectious components of disease. To provide a deeper context for how the resource can support research we show data in GtoImmuPdb relating to a case study on the targeting of vascular inflammation.

show abstract

Section: The Iuphar Guide To Immunopharmacology: Accessing the Datamentioning

confidence: 99%

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The anti-A/B antibody removal can be performed using different methods: double-filtration plasmapheresis in Japan, PP in the United States [3] and South Korea [4], antigen-specific IA in Europe. Regardless of the method used, the graft function is reported to be not significantly different among AB0-compatible and AB0-incompatible groups [5][6][7][8]. During classical PP, recipient plasma is removed and replaced by either albumin, fresh-frozen plasma, or a combination of both.…”

Section: To the Editormentioning

confidence: 99%

“…Due to the depletion of coagulation factors, PPs is thought to cause more bleeding complications when compared to IA [9,10]. The disadvantages of IA are two: a high cost if column is not reused and no removal of anti-HLA antibodies [5]. So in our clinic we use antigen-specific IA with columns that are for single patient use.…”

Section: To the Editormentioning

confidence: 99%

Successful adsorption of anti‐A/B antibodies with multiple personal use columns in AB0 incompatible kidney recipients: A single centre experience

Rimševičius

Bagarauskyte

Griskevicius

et al. 2016

J of Clinical Apheresis

View full text Add to dashboard Cite

“…Anti-ABO antibodies are either immunoglobulin (Ig) M (IgM) or IgG type. These antibodies are made during the development of the immune system against cross-reactive epitopes on the cell wall of gut bacteria, and their titer increases with age [18,19] .…”

Section: Blood Group Antigens and Antibodiesmentioning

confidence: 99%

Current progress in ABO-incompatible kidney transplantation

Koo

Yang

2015

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

ABO-incompatible kidney transplantation (ABOi KT) was introduced to expand the donor pool and minimize shortage of kidneys for transplantation. Because improved outcomes of ABOi KT were reported in Japan in the early 2000s, the number of ABOi KTs has been increasing worldwide. In addition, a better understanding of immune pathogenesis and subsequent aggressive immunosuppression has helped to make effective desensitization protocols. Current strategies of ABOi KT consist of pretransplant antibody removal using plasmapheresis or immunoadsorption to prevent hyperacute rejection and potent maintenance immunosuppression, such as tacrolimus and mycophenolate mofetil, to inhibit antibody-mediated rejection. Recent outcomes of ABOi KT are comparable with ABO-compatible KT. However, there are still many problems to be resolved. Very high anti-ABO antibody producers are difficult to desensitize. In addition, ABOi KT is associated with an increased risk of infection and possibly malignancy due to aggressive immunosuppression. Optimization of desensitization and patient-tailored immunosuppression protocols are needed to achieve better outcomes of ABOi KT. This review provides an overview of the history, immune mechanism, immunosuppressive protocol, outcomes, current obstacles, and future perspectives in ABOi KT.

show abstract

ABO-incompatible kidney transplantation

Cited by 11 publications

References 60 publications

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Successful adsorption of anti‐A/B antibodies with multiple personal use columns in AB0 incompatible kidney recipients: A single centre experience

Current progress in ABO-incompatible kidney transplantation

Contact Info

Product

Resources

About